MAXION-WHEELS
23.5.2022 18:39:13 CEST | Business Wire | Press release
Maxion Wheels, the world’s largest wheel manufacturer, and long-distance driver Rainer Zietlow and the Challenge4 team, successfully set a new Guinness World Record for driving to the highest altitude in the all-electric VW ID.4 GTX. Equipped with Maxion’s robust, lightweight and sustainable steel wheels, the team drove to the top of Bolivia’s Uturuncu volcano, 5,816 meters above sea level, breaking the previous record set in 2020 by approx. 45 meters of altitude.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005816/en/
Guinness World Records today presented Challenge4 with the official certificate during a press conference at the German Embassy in La Paz, Bolivia. “This world record underscores the performance capabilities of electric vehicles such as the VW ID.4 GTX," said Rainer Zietlow, Challenge4 Director. "On the difficult terrain we encountered getting to the top of the Uturuncu volcano, robust wheels were crucial for a safe journey. Maxion Wheels' lightweight, 18-inch steel wheels kept the vehicle on track ensuring maximum electric vehicle (EV) range and performance." With his world record drive, Zietlow also supports the local SOS Children's Village in La Paz.
Maxion Wheels actively supported the high-altitude challenge from the very beginning, underlining its commitment to sustainability and reducing CO2 emissions. As a leading wheel supplier for EV programs and new mobility fleets around the world, the Company offers many sustainable wheel options made with greener materials, less energy and more efficient designs and processes, supporting the automotive industry’s transition towards carbon neutral.
“Congratulations to Rainer and the Challenge4 team for setting a new Guinness World Record; Maxion Wheels is proud to be part of this record-breaking moment,” said Mark Gerardts, Vice President Global Sales and Marketing at Maxion Wheels. “Electric cars such as the VW ID.4 GTX are enabling a generation shift in vehicle design and sustainability, driving demand for greener wheel options. We believe low-carbon steel wheels can play an important role in the shift to zero-carbon mobility as the most cost-effective and environmentally friendly wheel option.”
For many mobility options, Maxion’s steel wheels are the preferred solution. With a comparable weight to aluminum, steel wheels are meeting vehicle manufacturers need for lighter components. And with six times lower CO2 production compared to conventional aluminum wheels, steel wheels offer additional significant sustainability benefits.
Learn more about the high-altitude Guinness World Record drive at vwid4-highaltitude.com.
ABOUT MAXION WHEELS
Maxion Wheels, a division of Iochpe-Maxion S.A., is the world’s largest steel and aluminum wheel supplier. Our low-carbon expertise and energy-efficient designs help cars, buses, trucks and trailers achieve real-world carbon footprint reductions. Maxion is proud of its diverse global teams and inclusive culture that powers every advance we make.
Maxion Wheels works with global vehicle manufacturers on wheels for personal mobility, transportation, agriculture, defence and off-highway applications. Our more than 10,000 employees operate out of 30 locations in 14 countries on five continents, including state-of-the-art technical centers in the Americas, Europe, and Asia. Together we produce more than 50 million wheels a year, making us the world’s largest producer and supplier of wheels. To learn more, please visit Maxion Wheels’ website at maxionwheels.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005816/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
